The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the ...

GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

Early fall is when asthma flare-ups peak in the U.S., and a warming climate is bad news for sufferers: It means more ...

The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor confidence in the company.

Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer. Shares ...

The UK FTSE 100 index increased by 0.3%, driven by significant gains in GSK following a settlement in the U.S. The market ...